Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 23 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cannabidiol (Primary)
  • Indications Lennox-Gastaut syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms GWPCARE3
  • Sponsors GW Pharmaceuticals; GW Research
  • Most Recent Events

    • 23 Sep 2019 According to an GW Pharmaceuticals media release, the European Commission (EC) has approved the marketing authorisation for EPIDYOLEX for use as adjunctive therapy of seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome, in conjunction with clobazam, for patients 2 years of age and older.
    • 25 Jun 2018 According to LGS foundation media release, the U.S. Food and Drug Administration (FDA) has approved EPIDIOLEX (cannabidiol / CBD) for the treatment of seizures associated with Lennox-Gastaut Syndrome (LGS) in patients two years age or older.
    • 17 May 2018 Results published in the New England Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top